Skip to main content
Top
Published in: BMC Cancer 1/2024

Open Access 01-12-2024 | Ovarian Cancer | Research

A novel TCGA-validated programmed cell-death-related signature of ovarian cancer

Authors: Xintong Cai, Jie Lin, Li Liu, Jianfeng Zheng, Qinying Liu, Liyan Ji, Yang Sun

Published in: BMC Cancer | Issue 1/2024

Login to get access

Abstract

Background

Ovarian cancer (OC) is a gynecological malignancy tumor with high recurrence and mortality rates. Programmed cell death (PCD) is an essential regulator in cancer metabolism, whose functions are still unknown in OC. Therefore, it is vital to determine the prognostic value and therapy response of PCD-related genes in OC.

Methods

By mining The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx) and Genecards databases, we constructed a prognostic PCD-related genes model and performed Kaplan-Meier (K-M) analysis and Receiver Operating Characteristic (ROC) curve for its predictive ability. A nomogram was created via Cox regression. We validated our model in train and test sets. Quantitative real-time PCR (qRT-PCR) was applied to identify the expression of our model genes. Finally, we analyzed functional analysis, immune infiltration, genomic mutation, tumor mutational burden (TMB) and drug sensitivity of patients in low- and high-risk group based on median scores.

Results

A ten-PCD-related gene signature including protein phosphatase 1 regulatory subunit 15 A (PPP1R15A), 8-oxoguanine-DNA glycosylase (OGG1), HECT and RLD domain containing E3 ubiquitin protein ligase family member 1 (HERC1), Caspase-2.(CASP2), Caspase activity and apoptosis inhibitor 1(CAAP1), RB transcriptional corepressor 1(RB1), Z-DNA binding protein 1 (ZBP1), CD3-epsilon (CD3E), Clathrin heavy chain like 1(CLTCL1), and CCAAT/enhancer-binding protein beta (CEBPB) was constructed. Risk score performed well with good area under curve (AUC) (AUC3 − year =0.728, AUC5 − year = 0.730). The nomogram based on risk score has good performance in predicting the prognosis of OC patients (AUC1 − year =0.781, AUC3 − year =0.759, AUC5 − year = 0.670). Kyoto encyclopedia of genes and genomes (KEGG) analysis showed that the erythroblastic leukemia viral oncogene homolog (ERBB) signaling pathway and focal adhesion were enriched in the high-risk group. Meanwhile, patients with high-risk scores had worse OS. In addition, patients with low-risk scores had higher immune-infiltrating cells and enhanced expression of checkpoints, programmed cell death 1 ligand 1 (PD-L1), indoleamine 2,3-dioxygenase 1 (IDO-1) and lymphocyte activation gene-3 (LAG3), and were more sensitive to A.443,654, GDC.0449, paclitaxel, gefitinib and cisplatin. Finally, qRT-PCR confirmed RB1, CAAP1, ZBP1, CEBPB and CLTCL1 over-expressed, while PPP1R15A, OGG1, CASP2, CD3E and HERC1 under-expressed in OC cell lines.

Conclusion

Our model could precisely predict the prognosis, immune status and drug sensitivity of OC patients.
Appendix
Available only for authorised users
Literature
1.
go back to reference Kuroki L, Guntupalli S. Treatment of epithelial ovarian cancer. BMJ (Clinical Res ed). 2020;371:m3773. Kuroki L, Guntupalli S. Treatment of epithelial ovarian cancer. BMJ (Clinical Res ed). 2020;371:m3773.
2.
go back to reference Orr B, Edwards R. Diagnosis and treatment of Ovarian Cancer. Hematol Oncol Clin N Am. 2018;32(6):943–64.CrossRef Orr B, Edwards R. Diagnosis and treatment of Ovarian Cancer. Hematol Oncol Clin N Am. 2018;32(6):943–64.CrossRef
3.
go back to reference Gaona-Luviano P, Medina-Gaona L, Magaña-Pérez K. Epidemiology of ovarian cancer. Chin Clin Oncol. 2020;9(4):47.PubMedCrossRef Gaona-Luviano P, Medina-Gaona L, Magaña-Pérez K. Epidemiology of ovarian cancer. Chin Clin Oncol. 2020;9(4):47.PubMedCrossRef
4.
go back to reference Armstrong D, et al. NCCN Guidelines® insights: ovarian Cancer, Version 3.2022. J Natl Compr Cancer Network: JNCCN. 2022;20(9):972–80.PubMedCrossRef Armstrong D, et al. NCCN Guidelines® insights: ovarian Cancer, Version 3.2022. J Natl Compr Cancer Network: JNCCN. 2022;20(9):972–80.PubMedCrossRef
5.
go back to reference Xu T, et al. Modulating the tumor immune microenvironment with nanoparticles: a sword for improving the efficiency of ovarian cancer immunotherapy. Front Immunol. 2022;13:1057850.PubMedPubMedCentralCrossRef Xu T, et al. Modulating the tumor immune microenvironment with nanoparticles: a sword for improving the efficiency of ovarian cancer immunotherapy. Front Immunol. 2022;13:1057850.PubMedPubMedCentralCrossRef
6.
go back to reference Laganà A, et al. Cytogenetic analysis of epithelial ovarian cancer’s stem cells: an overview on new diagnostic and therapeutic perspectives. Eur J Gynaecol Oncol. 2015;36(5):495–505.PubMed Laganà A, et al. Cytogenetic analysis of epithelial ovarian cancer’s stem cells: an overview on new diagnostic and therapeutic perspectives. Eur J Gynaecol Oncol. 2015;36(5):495–505.PubMed
7.
go back to reference Laganà A, et al. Epithelial ovarian cancer inherent resistance: may the pleiotropic interaction between reduced immunosurveillance and drug-resistant cells play a key role? Gynecologic Oncol Rep. 2016;18:57–8.CrossRef Laganà A, et al. Epithelial ovarian cancer inherent resistance: may the pleiotropic interaction between reduced immunosurveillance and drug-resistant cells play a key role? Gynecologic Oncol Rep. 2016;18:57–8.CrossRef
8.
9.
10.
go back to reference Zou Y, et al. Leveraging diverse cell-death patterns to predict the prognosis and drug sensitivity of triple-negative breast cancer patients after surgery. Int J Surg (London England). 2022;107:106936.CrossRef Zou Y, et al. Leveraging diverse cell-death patterns to predict the prognosis and drug sensitivity of triple-negative breast cancer patients after surgery. Int J Surg (London England). 2022;107:106936.CrossRef
12.
go back to reference Chen J, WZ, Fu K, Duan Y, Zhang M, Li K, Guo T, Yin R. Non-apoptotic cell death in ovarian cancer: treatment, resistance and prognosis. Biomed Pharmacother. 2022;150:112929.PubMedCrossRef Chen J, WZ, Fu K, Duan Y, Zhang M, Li K, Guo T, Yin R. Non-apoptotic cell death in ovarian cancer: treatment, resistance and prognosis. Biomed Pharmacother. 2022;150:112929.PubMedCrossRef
13.
go back to reference Zhang X, Yin QZ, Yang H. Interaction between p53 and Ras signaling controls DDP resistance via HDAC4- and HIF-1α-mediated regulation of apoptosis and autophagy. Theranostics. 2019;9(4):1096–114.PubMedPubMedCentralCrossRef Zhang X, Yin QZ, Yang H. Interaction between p53 and Ras signaling controls DDP resistance via HDAC4- and HIF-1α-mediated regulation of apoptosis and autophagy. Theranostics. 2019;9(4):1096–114.PubMedPubMedCentralCrossRef
14.
go back to reference Washington MN, Orozco GSAF, Sutton MN, Yang H, Wang Y, Mao W, Millward S, Ornelas A, Atkinson N, et al. ARHI (DIRAS3)-mediated autophagy-associated cell death enhances chemosensitivity to DDP in ovarian cancer cell lines and xenografts. Cell Death Dis. 2015;8(6):e1836.CrossRef Washington MN, Orozco GSAF, Sutton MN, Yang H, Wang Y, Mao W, Millward S, Ornelas A, Atkinson N, et al. ARHI (DIRAS3)-mediated autophagy-associated cell death enhances chemosensitivity to DDP in ovarian cancer cell lines and xenografts. Cell Death Dis. 2015;8(6):e1836.CrossRef
15.
go back to reference Tan C, et al. LncRNA HOTTIP inhibits cell pyroptosis by targeting miR-148a-3p/AKT2 axis in ovarian cancer. Cell Biol Int. 2021;45(7):1487–97.PubMedCrossRef Tan C, et al. LncRNA HOTTIP inhibits cell pyroptosis by targeting miR-148a-3p/AKT2 axis in ovarian cancer. Cell Biol Int. 2021;45(7):1487–97.PubMedCrossRef
17.
go back to reference Yang W, et al. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 2013;41:D955–61.PubMedCrossRef Yang W, et al. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 2013;41:D955–61.PubMedCrossRef
18.
go back to reference Geeleher P, Cox N, Huang R. pRRophetic: an R package for prediction of clinical chemotherapeutic response from tumor gene expression levels. PLoS ONE. 2014;9(9):e107468.PubMedPubMedCentralCrossRef Geeleher P, Cox N, Huang R. pRRophetic: an R package for prediction of clinical chemotherapeutic response from tumor gene expression levels. PLoS ONE. 2014;9(9):e107468.PubMedPubMedCentralCrossRef
19.
go back to reference Geeleher P, Cox N, Huang R. Clinical drug response can be predicted using baseline gene expression levels and in vitro drug sensitivity in cell lines. Genome Biol. 2014;15(3):R47.PubMedPubMedCentralCrossRef Geeleher P, Cox N, Huang R. Clinical drug response can be predicted using baseline gene expression levels and in vitro drug sensitivity in cell lines. Genome Biol. 2014;15(3):R47.PubMedPubMedCentralCrossRef
20.
go back to reference Huang H, Lin CX, Wu J, Zhang Q, Lin K, Liu Y, Lin B. A novel five-gene metabolism-related risk signature for predicting prognosis and immune infiltration in endometrial cancer: a TCGA data mining. Comput Biol Med. 2023;155:106632.PubMedCrossRef Huang H, Lin CX, Wu J, Zhang Q, Lin K, Liu Y, Lin B. A novel five-gene metabolism-related risk signature for predicting prognosis and immune infiltration in endometrial cancer: a TCGA data mining. Comput Biol Med. 2023;155:106632.PubMedCrossRef
21.
go back to reference Kollara A, et al. The adaptor protein VEPH1 interacts with the kinase domain of ERBB2 and impacts EGF signaling in ovarian cancer cells. Cell Signal. 2023;106:110634.PubMedCrossRef Kollara A, et al. The adaptor protein VEPH1 interacts with the kinase domain of ERBB2 and impacts EGF signaling in ovarian cancer cells. Cell Signal. 2023;106:110634.PubMedCrossRef
22.
go back to reference Zhao J, et al. FGFR3 phosphorylates EGFR to promote cisplatin-resistance in ovarian cancer. Biochem Pharmacol. 2021;190:114536.PubMedCrossRef Zhao J, et al. FGFR3 phosphorylates EGFR to promote cisplatin-resistance in ovarian cancer. Biochem Pharmacol. 2021;190:114536.PubMedCrossRef
23.
go back to reference Chung Y, et al. Overexpression of HER2/HER3 and clinical feature of ovarian cancer. J Gynecologic Oncol. 2019;30(5):e75.CrossRef Chung Y, et al. Overexpression of HER2/HER3 and clinical feature of ovarian cancer. J Gynecologic Oncol. 2019;30(5):e75.CrossRef
24.
go back to reference Yang W, et al. A TAZ-ANGPTL4-NOX2 Axis regulates ferroptotic cell death and Chemoresistance in epithelial ovarian Cancer. Mol cancer Research: MCR. 2020;18(1):79–90.PubMedCrossRef Yang W, et al. A TAZ-ANGPTL4-NOX2 Axis regulates ferroptotic cell death and Chemoresistance in epithelial ovarian Cancer. Mol cancer Research: MCR. 2020;18(1):79–90.PubMedCrossRef
25.
go back to reference van Zyl B, Tang D, Bowden N. Biomarkers of platinum resistance in ovarian cancer: what can we use to improve treatment. Endocrine-related Cancer. 2018;25(5):R303–18.PubMedCrossRef van Zyl B, Tang D, Bowden N. Biomarkers of platinum resistance in ovarian cancer: what can we use to improve treatment. Endocrine-related Cancer. 2018;25(5):R303–18.PubMedCrossRef
26.
go back to reference Chen J, et al. Non-apoptotic cell death in ovarian cancer: treatment, resistance and prognosis. Volume 150. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie; 2022. p. 112929. Chen J, et al. Non-apoptotic cell death in ovarian cancer: treatment, resistance and prognosis. Volume 150. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie; 2022. p. 112929.
27.
go back to reference Zhou J, et al. Tanshinone I attenuates the malignant biological properties of ovarian cancer by inducing apoptosis and autophagy via the inactivation of PI3K/AKT/mTOR pathway. Cell Prolif. 2020;53(2):e12739.PubMedCrossRef Zhou J, et al. Tanshinone I attenuates the malignant biological properties of ovarian cancer by inducing apoptosis and autophagy via the inactivation of PI3K/AKT/mTOR pathway. Cell Prolif. 2020;53(2):e12739.PubMedCrossRef
29.
32.
go back to reference Hu Z, et al. miR-29c-3p inhibits autophagy and cisplatin resistance in ovarian cancer by regulating FOXP1/ATG14 pathway. Cell Cycle (Georgetown Tex). 2020;19(2):193–206.PubMedCrossRef Hu Z, et al. miR-29c-3p inhibits autophagy and cisplatin resistance in ovarian cancer by regulating FOXP1/ATG14 pathway. Cell Cycle (Georgetown Tex). 2020;19(2):193–206.PubMedCrossRef
33.
35.
go back to reference Hollander M, et al. Mammalian GADD34, an apoptosis- and DNA damage-inducible gene. J Biol Chem. 1997;272(21):13731–7.PubMedCrossRef Hollander M, et al. Mammalian GADD34, an apoptosis- and DNA damage-inducible gene. J Biol Chem. 1997;272(21):13731–7.PubMedCrossRef
37.
go back to reference Wang R, et al. Single-cell RNA sequencing reveals the suppressive effect of PPP1R15A inhibitor Sephin1 in antitumor immunity. iScience. 2023;26(2):105954.PubMedPubMedCentralCrossRef Wang R, et al. Single-cell RNA sequencing reveals the suppressive effect of PPP1R15A inhibitor Sephin1 in antitumor immunity. iScience. 2023;26(2):105954.PubMedPubMedCentralCrossRef
38.
40.
go back to reference Mitra S, et al. Choreography of oxidative damage repair in mammalian genomes. Free Radic Biol Med. 2002;33(1):15–28.PubMedCrossRef Mitra S, et al. Choreography of oxidative damage repair in mammalian genomes. Free Radic Biol Med. 2002;33(1):15–28.PubMedCrossRef
41.
go back to reference Pázmándi K, et al. Oxidized base 8-oxoguanine, a product of DNA repair processes, contributes to dendritic cell activation. Volume 143. Free radical biology & medicine; 2019. pp. 209–20. Pázmándi K, et al. Oxidized base 8-oxoguanine, a product of DNA repair processes, contributes to dendritic cell activation. Volume 143. Free radical biology & medicine; 2019. pp. 209–20.
42.
go back to reference Zheng X, et al. Innate Immune responses to RSV infection facilitated by OGG1, an enzyme repairing oxidatively modified DNA base lesions. J Innate Immun. 2022;14(6):593–614.PubMedPubMedCentralCrossRef Zheng X, et al. Innate Immune responses to RSV infection facilitated by OGG1, an enzyme repairing oxidatively modified DNA base lesions. J Innate Immun. 2022;14(6):593–614.PubMedPubMedCentralCrossRef
43.
44.
go back to reference Arcand S, et al. OGG1 Cys326 variant, allelic imbalance of chromosome band 3p25.3 and TP53 mutations in ovarian cancer. Int J Oncol. 2005;27(5):1315–20.PubMed Arcand S, et al. OGG1 Cys326 variant, allelic imbalance of chromosome band 3p25.3 and TP53 mutations in ovarian cancer. Int J Oncol. 2005;27(5):1315–20.PubMed
45.
go back to reference Osorio A, et al. DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers. PLoS Genet. 2014;10(4):e1004256.PubMedPubMedCentralCrossRef Osorio A, et al. DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers. PLoS Genet. 2014;10(4):e1004256.PubMedPubMedCentralCrossRef
46.
go back to reference Giovannini S, et al. Synthetic lethality between BRCA1 deficiency and poly(ADP-ribose) polymerase inhibition is modulated by processing of endogenous oxidative DNA damage. Nucleic Acids Res. 2019;47(17):9132–43.PubMedPubMedCentralCrossRef Giovannini S, et al. Synthetic lethality between BRCA1 deficiency and poly(ADP-ribose) polymerase inhibition is modulated by processing of endogenous oxidative DNA damage. Nucleic Acids Res. 2019;47(17):9132–43.PubMedPubMedCentralCrossRef
47.
go back to reference Sánchez-Tena SC-R, Schneider M. Rosa, Jose Luis Functional and pathological relevance of HERC family proteins: a decade later. Cell Mol Life Sci. 2016;73(10):1955–68.PubMedCrossRef Sánchez-Tena SC-R, Schneider M. Rosa, Jose Luis Functional and pathological relevance of HERC family proteins: a decade later. Cell Mol Life Sci. 2016;73(10):1955–68.PubMedCrossRef
48.
go back to reference Rossi F et al. HERC1 regulates breast Cancer cells Migration and Invasion. Cancers, 2021. 13(6). Rossi F et al. HERC1 regulates breast Cancer cells Migration and Invasion. Cancers, 2021. 13(6).
49.
go back to reference Kopeina G, Zhivotovsky B. Caspase-2 as a master regulator of genomic stability. Trends Cell Biol. 2021;31(9):712–20.PubMedCrossRef Kopeina G, Zhivotovsky B. Caspase-2 as a master regulator of genomic stability. Trends Cell Biol. 2021;31(9):712–20.PubMedCrossRef
50.
go back to reference Maney S, et al. RAIDD mediates TLR3 and IRF7 driven type I Interferon Production. Cell Physiol Biochemistry: Int J Experimental Cell Physiol Biochem Pharmacol. 2016;39(4):1271–80.CrossRef Maney S, et al. RAIDD mediates TLR3 and IRF7 driven type I Interferon Production. Cell Physiol Biochemistry: Int J Experimental Cell Physiol Biochem Pharmacol. 2016;39(4):1271–80.CrossRef
53.
go back to reference Zhang H, et al. MKL1/miR-5100/CAAP1 loop regulates autophagy and apoptosis in gastric cancer cells. Volume 22. Neoplasia (New York, N.Y.),; 2020. pp. 220–30. 5. Zhang H, et al. MKL1/miR-5100/CAAP1 loop regulates autophagy and apoptosis in gastric cancer cells. Volume 22. Neoplasia (New York, N.Y.),; 2020. pp. 220–30. 5.
55.
go back to reference Wang J, et al. Mutational analysis of microsatellite-stable gastrointestinal cancer with high tumour mutational burden: a retrospective cohort study. Lancet Oncol. 2023;24(2):151–61.PubMedPubMedCentralCrossRef Wang J, et al. Mutational analysis of microsatellite-stable gastrointestinal cancer with high tumour mutational burden: a retrospective cohort study. Lancet Oncol. 2023;24(2):151–61.PubMedPubMedCentralCrossRef
58.
go back to reference Karki R, Kanneganti T. ADAR1 and ZBP1 in innate immunity, cell death, and disease. Trends in immunology; 2023. Karki R, Kanneganti T. ADAR1 and ZBP1 in innate immunity, cell death, and disease. Trends in immunology; 2023.
61.
go back to reference Dong D, Lin ZL, Zhang J, Zhu B, Li Y.et al, structural basis of assembly of the human T cell receptor-CD3 complex. Nature. 2019;573:546–52.PubMedCrossRef Dong D, Lin ZL, Zhang J, Zhu B, Li Y.et al, structural basis of assembly of the human T cell receptor-CD3 complex. Nature. 2019;573:546–52.PubMedCrossRef
63.
go back to reference Zhang M et al. The Immune subtypes and Landscape of Advanced-Stage Ovarian Cancer. Vaccines, 2022. 10(9). Zhang M et al. The Immune subtypes and Landscape of Advanced-Stage Ovarian Cancer. Vaccines, 2022. 10(9).
64.
65.
go back to reference Long KR, Ramesh TJ, McCormick V, Buckler MK. Cloning and characterization of a novel human clathrin heavy chain gene. Genomics. 1996;35:466–72.PubMedCrossRef Long KR, Ramesh TJ, McCormick V, Buckler MK. Cloning and characterization of a novel human clathrin heavy chain gene. Genomics. 1996;35:466–72.PubMedCrossRef
66.
go back to reference Sens-Abuázar C, et al. Down-regulation of ANAPC13 and CLTCL1: early events in the Progression of Preinvasive Ductal Carcinoma of the breast. Translational Oncol. 2012;5(2):113–23.CrossRef Sens-Abuázar C, et al. Down-regulation of ANAPC13 and CLTCL1: early events in the Progression of Preinvasive Ductal Carcinoma of the breast. Translational Oncol. 2012;5(2):113–23.CrossRef
67.
go back to reference Zahnow C. CCAAT/enhancer-binding protein beta: its role in breast cancer and associations with receptor tyrosine kinases. Expert Rev Mol Med. 2009;11:e12.PubMedPubMedCentralCrossRef Zahnow C. CCAAT/enhancer-binding protein beta: its role in breast cancer and associations with receptor tyrosine kinases. Expert Rev Mol Med. 2009;11:e12.PubMedPubMedCentralCrossRef
68.
69.
go back to reference Tan J, et al. C/EBPβ promotes poly(ADP-ribose) polymerase inhibitor resistance by enhancing homologous recombination repair in high-grade serous ovarian cancer. Oncogene. 2021;40(22):3845–58.PubMedPubMedCentralCrossRef Tan J, et al. C/EBPβ promotes poly(ADP-ribose) polymerase inhibitor resistance by enhancing homologous recombination repair in high-grade serous ovarian cancer. Oncogene. 2021;40(22):3845–58.PubMedPubMedCentralCrossRef
70.
go back to reference Wang Z. ErbB receptors and Cancer methods in molecular biology. (Clifton N J). 2017;1652:3–35. Wang Z. ErbB receptors and Cancer methods in molecular biology. (Clifton N J). 2017;1652:3–35.
71.
go back to reference Moscatello C et al. Emerging role of oxidative stress on EGFR and OGG1-BER cross-regulation: implications in thyroid physiopathology. Cells, 2022. 11(5). Moscatello C et al. Emerging role of oxidative stress on EGFR and OGG1-BER cross-regulation: implications in thyroid physiopathology. Cells, 2022. 11(5).
72.
go back to reference Craig D, et al. Genome and transcriptome sequencing in prospective metastatic triple-negative breast cancer uncovers therapeutic vulnerabilities. Mol Cancer Ther. 2013;12(1):104–16.PubMedCrossRef Craig D, et al. Genome and transcriptome sequencing in prospective metastatic triple-negative breast cancer uncovers therapeutic vulnerabilities. Mol Cancer Ther. 2013;12(1):104–16.PubMedCrossRef
73.
go back to reference Bonin S et al. PI3K/AKT Signaling in Breast Cancer Molecular Subtyping and Lymph Node InvolvementS Disease markers, 2019. 2019: p. 7832376. Bonin S et al. PI3K/AKT Signaling in Breast Cancer Molecular Subtyping and Lymph Node InvolvementS Disease markers, 2019. 2019: p. 7832376.
74.
go back to reference Snyder L, Astsaturov I, Weiner L. Overview of monoclonal antibodies and small molecules targeting the epidermal growth factor receptor pathway in colorectal cancer. Clin Colorectal Cancer, 2005: p. S71–80. Snyder L, Astsaturov I, Weiner L. Overview of monoclonal antibodies and small molecules targeting the epidermal growth factor receptor pathway in colorectal cancer. Clin Colorectal Cancer, 2005: p. S71–80.
76.
go back to reference Sidhanth C, et al. Phosphoproteome of signaling by ErbB2 in ovarian cancer cells. Biochim et Biophys acta Proteins Proteom. 2022;1870(4):140768.CrossRef Sidhanth C, et al. Phosphoproteome of signaling by ErbB2 in ovarian cancer cells. Biochim et Biophys acta Proteins Proteom. 2022;1870(4):140768.CrossRef
77.
go back to reference Zeng X, et al. M2-like tumor-associated macrophages-secreted EGF promotes epithelial ovarian cancer metastasis via activating EGFR-ERK signaling and suppressing lncRNA LIMT expression. Cancer Biol Ther. 2019;20(7):956–66.PubMedPubMedCentralCrossRef Zeng X, et al. M2-like tumor-associated macrophages-secreted EGF promotes epithelial ovarian cancer metastasis via activating EGFR-ERK signaling and suppressing lncRNA LIMT expression. Cancer Biol Ther. 2019;20(7):956–66.PubMedPubMedCentralCrossRef
78.
go back to reference Martin-Lluesma S, et al. Are dendritic cells the most appropriate therapeutic vaccine for patients with ovarian cancer? Curr Opin Biotechnol. 2020;65:190–6.PubMedCrossRef Martin-Lluesma S, et al. Are dendritic cells the most appropriate therapeutic vaccine for patients with ovarian cancer? Curr Opin Biotechnol. 2020;65:190–6.PubMedCrossRef
79.
80.
go back to reference Filipchiuk C et al. BIRC5/Survivin Expression as a Non-Invasive Biomarker of Endometriosis Diagnostics (Basel, Switzerland), 2020. 10(8). Filipchiuk C et al. BIRC5/Survivin Expression as a Non-Invasive Biomarker of Endometriosis Diagnostics (Basel, Switzerland), 2020. 10(8).
81.
go back to reference Králíčková M, et al. Endometriosis and risk of ovarian cancer: what do we know? Arch Gynecol Obstet. 2020;301(1):1–10.PubMedCrossRef Králíčková M, et al. Endometriosis and risk of ovarian cancer: what do we know? Arch Gynecol Obstet. 2020;301(1):1–10.PubMedCrossRef
82.
go back to reference Anadon C, et al. Ovarian cancer immunogenicity is governed by a narrow subset of progenitor tissue-resident memory T cells. Cancer Cell. 2022;40(5):545–e55713.PubMedPubMedCentralCrossRef Anadon C, et al. Ovarian cancer immunogenicity is governed by a narrow subset of progenitor tissue-resident memory T cells. Cancer Cell. 2022;40(5):545–e55713.PubMedPubMedCentralCrossRef
84.
go back to reference De Smaele E, Ferretti E, Gulino A. Vismodegib, a small-molecule inhibitor of the hedgehog pathway for the treatment of advanced cancers. Curr Opin Invest Drugs (London England: 2000). 2010;11(6):707–18. De Smaele E, Ferretti E, Gulino A. Vismodegib, a small-molecule inhibitor of the hedgehog pathway for the treatment of advanced cancers. Curr Opin Invest Drugs (London England: 2000). 2010;11(6):707–18.
85.
go back to reference Zhou Q, et al. GDC-0449 improves the antitumor activity of nano-doxorubicin in pancreatic cancer in a fibroblast-enriched microenvironment. Sci Rep. 2017;7(1):13379.PubMedPubMedCentralCrossRef Zhou Q, et al. GDC-0449 improves the antitumor activity of nano-doxorubicin in pancreatic cancer in a fibroblast-enriched microenvironment. Sci Rep. 2017;7(1):13379.PubMedPubMedCentralCrossRef
87.
go back to reference Kadife E et al. Paclitaxel-Induced src activation is inhibited by Dasatinib Treatment, independently of Cancer Stem Cell properties, in a mouse model of Ovarian Cancer. Cancers, 2019. 11(2). Kadife E et al. Paclitaxel-Induced src activation is inhibited by Dasatinib Treatment, independently of Cancer Stem Cell properties, in a mouse model of Ovarian Cancer. Cancers, 2019. 11(2).
88.
go back to reference Davidson B, Secord A. Profile of pazopanib and its potential in the treatment of epithelial ovarian cancer. Int J Women’s Health. 2014;6:289–300. Davidson B, Secord A. Profile of pazopanib and its potential in the treatment of epithelial ovarian cancer. Int J Women’s Health. 2014;6:289–300.
89.
go back to reference Weigel M, et al. Nilotinib in combination with carboplatin and paclitaxel is a candidate for ovarian cancer treatment. Oncology. 2014;87(4):232–45.PubMedCrossRef Weigel M, et al. Nilotinib in combination with carboplatin and paclitaxel is a candidate for ovarian cancer treatment. Oncology. 2014;87(4):232–45.PubMedCrossRef
Metadata
Title
A novel TCGA-validated programmed cell-death-related signature of ovarian cancer
Authors
Xintong Cai
Jie Lin
Li Liu
Jianfeng Zheng
Qinying Liu
Liyan Ji
Yang Sun
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-024-12245-2

Other articles of this Issue 1/2024

BMC Cancer 1/2024 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine